Araştırma Makalesi
BibTex RIS Kaynak Göster
Yıl 2019, Cilt: 2 Sayı: 2, 1 - 7, 31.12.2019

Öz

Kaynakça

  • References 1) Fox RI (2005) Sjogren's syndrome. Lancet 366(9482):321-31.2) Kassan SS, Moutsopoulos HM (2004) Clinical Manifestations and Early Diagnosis of Sjögren Syndrome. Arch Intern Med 164:1275-1284.3) Moutsopoulos HM (2014) Sjögren's syndrome: a forty-year scientific journey. J Autoimmun 51:1-9. doi: 10.1016/j.jaut.2014.01.0014) Palm Q, Garen T, Enger TB, Jensen JL, Lund MB, Aalokken TM, Gran JT (2013) Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality-a retrospective study based on registry data. Rheumatology (Oxford) 52(1):173-9. doi: 10.1093/rheumatology/kes3115) Voulgarelis M, Tzioufas AG, Moutsopoulos HM (2008) Mortality in Sjögren's syndrome. Clin Exp Rheumatol 26(5 Suppl 51):S66-71. 6) Weng MY, Huang YT, Liu MF, Lu TH (2011) Incidence and mortality of treated primary Sjogren's syndrome in Taiwan: a population-based study. J Rheumatol 38(4):706-8. 7) Kruize AA, Hené RJ, van der Heide A, Bodeutsch C, de Wilde PC, van Bijsterveld OP, de Jong J, Feltkamp TE, Kater L, Bijlsma JW (1996) Long-term followup of patients Arthritis Rheum 39:297–303. 8) Davidson BK, Kelly CA, Griffiths ID (1999) Primary Sjögren’s syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford) 38:245–3. 9) Martens PB, Pillemer SR, Jacobsson LT, O'Fallon WM, Matteson EL (1999) Survivorship in a population based cohort of patients with Sjögren’s syndrome, 1976–1992. J Rheumatol 26:1296–300. 10) Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A (2001) A longitudinal cohort study of Finnish patients with primary Sjögren’s syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 60:467–72. 11) Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum 46:741–7.12) Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA (2006) Epidemiology of primary Sjögren’s syndrome in north-west Greece, 1982–2003. Rheumatology (Oxford) 45:187–91.13) Brito-Zerón P, Kostov B, Solans R, Fraile G, Suárez-Cuervo C, Casanovas A, et al (2014) Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis. doi: 10.1136/annrheumdis-2014-206418.14) Shiboski SC, Shiboski CH, Criswell LA, Baer AN, Challacombe S, Lanfranchi H, et al (2012) American Collage of Rheumatology Classification Criteria for Sjögren’s Syndrome: A Data-Driven, Expert Consensus Approach in the Sjögren’s International Collaborative Clinical Alliance Cohort. Arthritis Care Res (Hoboken) 64(4):475-87.15) Daniels TE. Labial salivary gland biopsy in Sjögren’s syndrome: assessment on a diagnostic criterion in 362 suspected cases. Arthritis Rheum 1984;27:147–56.16) Kvarnström M, Ottosson V, Nordmark B, Wahren-Herlenius M (2015) Incident cases of primary Sjögren's syndrome during a 5-year period in Stockholm County: a descriptive study of the patients and their characteristics. Scand J Rheumatol 44(2):135-42. doi: 10.3109/03009742.2014.931457.17) Sardu C, Cocco E, Mereu A, Massa R, Cuccu A, Marrosu MG, Contu P (2012) Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PLoS One 7(3):e32487. doi: 10.1371/journal.pone.003248718) Kabasakal Y, Kitapcioglu G, Turk T, Oder G, Durusoy R, Mete N, Egrilmez S, Akalin T (2006) The prevalence of Sjogren’s syndrome in adult women. Scand J Rheumatol 35(5):379-83. 19) Birlik M, Akar S, Gurler O, Sari I, Birlik B, Sarioglu S, Oktem MA, Saglam F, Can G, Kayahan H, Akkoc N, Onen F (2009) Prevalence of primary Sjogren's syndrome in Turkey: a population-based epidemiological study. Int J Clin Pract. 63(6):954-61. doi: 10.1111/j.1742-1241.2008.01749.x. 20) Yazısız V, Avcı AB, Erbasan F, Kiriş E, Terzioğlu E (2009) Diagnostic performance of minor salivary gland biopsy, serological and clinical data in Sjogren’s syndrome: a retrospective analysis. Rheumatol Int 29:403–409, doi: 10.1007/s00296-008-0698-1. 21) Çefle A, Yazıcı A, Turgut T (2010) Primer Sjögren sendromu olan 25 hastanın klinik ve laboratuar bulgularının değerlendirilmesi. Tıp Araştırmaları Dergisi 8(1) : 22 – 26, http://tader.org/files/EJGM-54.pdf22) Taşkıran I (2010) Sjögren Sendromunun Klinik, Biyokimyasal Özellikleri ve Keratokonjuktivitis Sikka’dan Farklılıkları. Uzmanlık Tezi. Hacettepe Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı. Ankara 23) Manganelli P, Fietta P, Quaini F (2006) Hematologic manifestations of primary Sjögren’s syndrome. Clin Exp Rheumatol 24: 438-448.24) Ramos-Casals M, Brito-Zeron P, Solans R, Camps MT, Casanovas A, Sopena B, et al (2014) Systemic involvement in primary Sjogren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients. Rheumatology (Oxford) 53(2):321-31. doi: 10.1093/rheumatology/ket349. 25) Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, et al (2008) Primary Sjogren syndrome in Spain:clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 87(4):210-9. doi: 10.1097/MD. 0b013e318181e6af.26) Pavlakis PP, Alexopoulos H, Kosmidis ML, Stamboulis E, Routsias JG, Tzartos SJ, Tzioufas AG, Moutsopoulos HM, Dalakas MC (2010) Peripheral neuropathies in Sjogren syndrome: a new reappraisal J Neurol Neurosurg Psychiatry 82(7):798-802. doi: 10.1136/jnnp.2010.22210927) Binder A, Snaith ML, Isenberg D (1988) Sjogren’s syndrome: a study of its neurological complications. Br J Rheumatol 27:275-8028) Harboe E, Tjensvoll AB, Maroni S, Goransson LG, Greve OJ, Beyer MK, Herigstad A, Kvaløy JT, Omdal R (2009) Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjogren syndrome: a comparative population-based study. Ann Rheum Dis 68(10):1541-6. doi: 10.1136/ard.2008.098301.29) Yazısız V, Arslan G, Özbudak AH, Türker S, Erbasan F, Avcı AB, Ozbudak O, Terzioglu (2010) Lung involvement in patients with primary Sjögren’s syndrome: what are the predictors? Rheumatol Int 30:1317–1324 doi: 10.1007/s00296-009-1152-8.30) Ibn Yacoub Y, Rostom S, Laatiris A, Hajjaj-Hassouni N (2012) Primary Sjögren’s syndrome in Moroccan patients: characteristics, fatigue and quality of life. Rheumatol Int 32(9):2637-43. doi: 10.1007/s00296-011-2009-5.31) Cain HC, Noble PW, Matthay RA. Pulmonary manifestations of Sjogren’s syndrome. Clin Chest Med 1998; 19:687-99.32) Quismorio FP (1996) Pulmonary involvement in primary Sjogren’s syndrome. Curr Opin Pulm Med 2:424-8.33) Gardiner P, Ward C, Allison A, Ashcroft T, Simpson W, Walters H, Kelly C (1993) Pleuropulmonary abnormalities in primary Sjogren’s syndrome. J Rheumatol 20(5):831-734) Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho JV, Saldiva PH, de Carvalho CR (1996) Interstitial lung disease in primary Sjogren’s syndrome. Clinical–pathological evaluation and response to treatment. Am J Respir Crit Care Med 154:794–935) Davidson BK, Kelly CA, Griffiths ID (2000) Ten-year follow-up of pulmonary function in patients with primary Sjogren’s syndrome. Ann Rheum Dis 59:709–71236) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classiffication of the Idiopathic Interstitial Pneumonias (2002) This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277–30437) Panchovska M, Sheitanov Y, Uzunov N (2004) Mortality of Bulgarian patients with primary and secondary Sjogren’s syndrome. Bratisl Lek Listy 105(12):43438) Lazarus MN, Robinson D, Mak V, Moller H, Isenberg DA (2006) Incidence of cancer in a cohort of patients with primary Sjogren’s syndrome. Rheumatology(Oxford) 45:1012–101539) Valesini G, Priori R, Bavoillot D, Osborn J, Danieli MG, Del Papa N et al (1997) Differential risk of non-Hodgkin’s lymphoma in Italian patients with primary Sjögren’s syndrome. J Rheumatol 24:2376–80.40) Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LTH (2006) Lymphoma and other malignancies in primary Sjogren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65:796–80341) Zhang W, Feng S, Yan S, Zhao Y, Li M, Sun J, Zhang FC, Cui Q, Dong Y (2010) Incidence of malignancy in primary Sjogren’s syndrome in a Chinese cohort. Rheumatology (Oxford) 49:571–7. 42) Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89(6):888–92.

DEMOGRAPHIC AND CLINICAL FEATURES OF PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME IN ANTALYA

Yıl 2019, Cilt: 2 Sayı: 2, 1 - 7, 31.12.2019

Öz

Abstract

Background: Sjögren’s syndrome (SS) is an autoimmune disease with
a broad range of systemic manifestations.
This study was conducted to determine demographic and clinical features of primary SS patients.

 

Methods: In this study were included the patients with primary
SS (pSS) diagnosed between 2004-2014 years at the Akdeniz University Hospital,
Antalya, Turkey
. The
clinical and laboratory features were retrospectively obtained from medical
charts.

 

Results: We had 718 patients with suspected pSS at
10 years
. 372 patients were classified as pSS according
to 2012 American Collage of Rheumatology Classification Criteria for Sjögren’s
Syndrome.
pSS was more frequent among women and ratio women/men
was 11/1.
The mean age at the time of
pSS diagnosis was
50.3±11.81 years. In men, pSS was diagnosed at an older age, and lung
involvement was common than women.
Joint involvement is the
most common extraglandular involvement. Anemia is present in 21.1 % of the
patients. Malignancy was diagnosed in 14 patients (3.8%) and
18 patients died (4.8%) during follow-up. Hydroxychloroquine
is the most preferred drug as a therapeutic agent

 















Conclusions: Features of primary SS obtained in this study are
similar to those found in some national and international studies, but we
observed lung involvement higher male than female.

Kaynakça

  • References 1) Fox RI (2005) Sjogren's syndrome. Lancet 366(9482):321-31.2) Kassan SS, Moutsopoulos HM (2004) Clinical Manifestations and Early Diagnosis of Sjögren Syndrome. Arch Intern Med 164:1275-1284.3) Moutsopoulos HM (2014) Sjögren's syndrome: a forty-year scientific journey. J Autoimmun 51:1-9. doi: 10.1016/j.jaut.2014.01.0014) Palm Q, Garen T, Enger TB, Jensen JL, Lund MB, Aalokken TM, Gran JT (2013) Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality-a retrospective study based on registry data. Rheumatology (Oxford) 52(1):173-9. doi: 10.1093/rheumatology/kes3115) Voulgarelis M, Tzioufas AG, Moutsopoulos HM (2008) Mortality in Sjögren's syndrome. Clin Exp Rheumatol 26(5 Suppl 51):S66-71. 6) Weng MY, Huang YT, Liu MF, Lu TH (2011) Incidence and mortality of treated primary Sjogren's syndrome in Taiwan: a population-based study. J Rheumatol 38(4):706-8. 7) Kruize AA, Hené RJ, van der Heide A, Bodeutsch C, de Wilde PC, van Bijsterveld OP, de Jong J, Feltkamp TE, Kater L, Bijlsma JW (1996) Long-term followup of patients Arthritis Rheum 39:297–303. 8) Davidson BK, Kelly CA, Griffiths ID (1999) Primary Sjögren’s syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford) 38:245–3. 9) Martens PB, Pillemer SR, Jacobsson LT, O'Fallon WM, Matteson EL (1999) Survivorship in a population based cohort of patients with Sjögren’s syndrome, 1976–1992. J Rheumatol 26:1296–300. 10) Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A (2001) A longitudinal cohort study of Finnish patients with primary Sjögren’s syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 60:467–72. 11) Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum 46:741–7.12) Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA (2006) Epidemiology of primary Sjögren’s syndrome in north-west Greece, 1982–2003. Rheumatology (Oxford) 45:187–91.13) Brito-Zerón P, Kostov B, Solans R, Fraile G, Suárez-Cuervo C, Casanovas A, et al (2014) Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis. doi: 10.1136/annrheumdis-2014-206418.14) Shiboski SC, Shiboski CH, Criswell LA, Baer AN, Challacombe S, Lanfranchi H, et al (2012) American Collage of Rheumatology Classification Criteria for Sjögren’s Syndrome: A Data-Driven, Expert Consensus Approach in the Sjögren’s International Collaborative Clinical Alliance Cohort. Arthritis Care Res (Hoboken) 64(4):475-87.15) Daniels TE. Labial salivary gland biopsy in Sjögren’s syndrome: assessment on a diagnostic criterion in 362 suspected cases. Arthritis Rheum 1984;27:147–56.16) Kvarnström M, Ottosson V, Nordmark B, Wahren-Herlenius M (2015) Incident cases of primary Sjögren's syndrome during a 5-year period in Stockholm County: a descriptive study of the patients and their characteristics. Scand J Rheumatol 44(2):135-42. doi: 10.3109/03009742.2014.931457.17) Sardu C, Cocco E, Mereu A, Massa R, Cuccu A, Marrosu MG, Contu P (2012) Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PLoS One 7(3):e32487. doi: 10.1371/journal.pone.003248718) Kabasakal Y, Kitapcioglu G, Turk T, Oder G, Durusoy R, Mete N, Egrilmez S, Akalin T (2006) The prevalence of Sjogren’s syndrome in adult women. Scand J Rheumatol 35(5):379-83. 19) Birlik M, Akar S, Gurler O, Sari I, Birlik B, Sarioglu S, Oktem MA, Saglam F, Can G, Kayahan H, Akkoc N, Onen F (2009) Prevalence of primary Sjogren's syndrome in Turkey: a population-based epidemiological study. Int J Clin Pract. 63(6):954-61. doi: 10.1111/j.1742-1241.2008.01749.x. 20) Yazısız V, Avcı AB, Erbasan F, Kiriş E, Terzioğlu E (2009) Diagnostic performance of minor salivary gland biopsy, serological and clinical data in Sjogren’s syndrome: a retrospective analysis. Rheumatol Int 29:403–409, doi: 10.1007/s00296-008-0698-1. 21) Çefle A, Yazıcı A, Turgut T (2010) Primer Sjögren sendromu olan 25 hastanın klinik ve laboratuar bulgularının değerlendirilmesi. Tıp Araştırmaları Dergisi 8(1) : 22 – 26, http://tader.org/files/EJGM-54.pdf22) Taşkıran I (2010) Sjögren Sendromunun Klinik, Biyokimyasal Özellikleri ve Keratokonjuktivitis Sikka’dan Farklılıkları. Uzmanlık Tezi. Hacettepe Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı. Ankara 23) Manganelli P, Fietta P, Quaini F (2006) Hematologic manifestations of primary Sjögren’s syndrome. Clin Exp Rheumatol 24: 438-448.24) Ramos-Casals M, Brito-Zeron P, Solans R, Camps MT, Casanovas A, Sopena B, et al (2014) Systemic involvement in primary Sjogren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients. Rheumatology (Oxford) 53(2):321-31. doi: 10.1093/rheumatology/ket349. 25) Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, et al (2008) Primary Sjogren syndrome in Spain:clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 87(4):210-9. doi: 10.1097/MD. 0b013e318181e6af.26) Pavlakis PP, Alexopoulos H, Kosmidis ML, Stamboulis E, Routsias JG, Tzartos SJ, Tzioufas AG, Moutsopoulos HM, Dalakas MC (2010) Peripheral neuropathies in Sjogren syndrome: a new reappraisal J Neurol Neurosurg Psychiatry 82(7):798-802. doi: 10.1136/jnnp.2010.22210927) Binder A, Snaith ML, Isenberg D (1988) Sjogren’s syndrome: a study of its neurological complications. Br J Rheumatol 27:275-8028) Harboe E, Tjensvoll AB, Maroni S, Goransson LG, Greve OJ, Beyer MK, Herigstad A, Kvaløy JT, Omdal R (2009) Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjogren syndrome: a comparative population-based study. Ann Rheum Dis 68(10):1541-6. doi: 10.1136/ard.2008.098301.29) Yazısız V, Arslan G, Özbudak AH, Türker S, Erbasan F, Avcı AB, Ozbudak O, Terzioglu (2010) Lung involvement in patients with primary Sjögren’s syndrome: what are the predictors? Rheumatol Int 30:1317–1324 doi: 10.1007/s00296-009-1152-8.30) Ibn Yacoub Y, Rostom S, Laatiris A, Hajjaj-Hassouni N (2012) Primary Sjögren’s syndrome in Moroccan patients: characteristics, fatigue and quality of life. Rheumatol Int 32(9):2637-43. doi: 10.1007/s00296-011-2009-5.31) Cain HC, Noble PW, Matthay RA. Pulmonary manifestations of Sjogren’s syndrome. Clin Chest Med 1998; 19:687-99.32) Quismorio FP (1996) Pulmonary involvement in primary Sjogren’s syndrome. Curr Opin Pulm Med 2:424-8.33) Gardiner P, Ward C, Allison A, Ashcroft T, Simpson W, Walters H, Kelly C (1993) Pleuropulmonary abnormalities in primary Sjogren’s syndrome. J Rheumatol 20(5):831-734) Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho JV, Saldiva PH, de Carvalho CR (1996) Interstitial lung disease in primary Sjogren’s syndrome. Clinical–pathological evaluation and response to treatment. Am J Respir Crit Care Med 154:794–935) Davidson BK, Kelly CA, Griffiths ID (2000) Ten-year follow-up of pulmonary function in patients with primary Sjogren’s syndrome. Ann Rheum Dis 59:709–71236) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classiffication of the Idiopathic Interstitial Pneumonias (2002) This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277–30437) Panchovska M, Sheitanov Y, Uzunov N (2004) Mortality of Bulgarian patients with primary and secondary Sjogren’s syndrome. Bratisl Lek Listy 105(12):43438) Lazarus MN, Robinson D, Mak V, Moller H, Isenberg DA (2006) Incidence of cancer in a cohort of patients with primary Sjogren’s syndrome. Rheumatology(Oxford) 45:1012–101539) Valesini G, Priori R, Bavoillot D, Osborn J, Danieli MG, Del Papa N et al (1997) Differential risk of non-Hodgkin’s lymphoma in Italian patients with primary Sjögren’s syndrome. J Rheumatol 24:2376–80.40) Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LTH (2006) Lymphoma and other malignancies in primary Sjogren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65:796–80341) Zhang W, Feng S, Yan S, Zhao Y, Li M, Sun J, Zhang FC, Cui Q, Dong Y (2010) Incidence of malignancy in primary Sjogren’s syndrome in a Chinese cohort. Rheumatology (Oxford) 49:571–7. 42) Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89(6):888–92.
Toplam 1 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Sağlık Kurumları Yönetimi
Bölüm Makaleler
Yazarlar

Mesut Göçer

Yayımlanma Tarihi 31 Aralık 2019
Yayımlandığı Sayı Yıl 2019 Cilt: 2 Sayı: 2

Kaynak Göster

APA Göçer, M. (2019). DEMOGRAPHIC AND CLINICAL FEATURES OF PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME IN ANTALYA. Turkish Journal of Health Science and Life, 2(2), 1-7.